Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19

NCT04356937 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04356937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04356937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2020
Completion date
August 27, 2020
Enrollment
243 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov 2